Equol status modifies the association of soy intake and mammographic density in a sample of postmenopausal women

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Barbara J FuhrmanPaola C Muti

Abstract

Only 30% to 50% of people produce the daidzein-metabolite equol after eating soy. We conducted a cross-sectional study of the associations between equol status, intake of soy foods, and mammographic density in a sample of postmenopausal women recruited at a radiology clinic near Buffalo, New York. Participants were 48 to 82 years old, had no history of cancer or breast reduction/augmentation, and no recent use of antibiotics or hormones. Percent density was measured by computer-assisted analysis of digitized images of craniocaudal films. Equol status was assessed using a soy-challenge protocol and usual soy intake by questionnaire. General linear models were used to assess independent and joint effects of equol status and intake of soy on multivariate adjusted percent density (covariates included age, body mass index, parity, age at first birth, and ever use of combined hormone therapy). Of 325 enrolled, 232 (71%) participants completed study assessments and are included in the present analysis. Mean percent density was 34% (+/-18%). Seventy-five (30%) participants were producers of equol. Forty-three (19%) participants reported regularly eating >1 soy food or supplement/wk. There were no significant independent associations of...Continue Reading

Citations

Mar 1, 2012·European Journal of Nutrition·Dana ShorNatalie J Thatcher
Nov 30, 2007·Breast Cancer Research and Treatment·Gertraud MaskarinecLaurence N Kolonel
Sep 30, 2008·Breast Cancer Research and Treatment·Charlotte AtkinsonJohanna W Lampe
Nov 1, 2011·Breast Cancer Research and Treatment·Jennifer StoneJohn Hopper
Nov 26, 2010·The Proceedings of the Nutrition Society·Pamela J Magee
Aug 7, 2012·Nutrition and Cancer·Sarah J LowryAmy Trentham-Dietz
Dec 10, 2008·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Anna H WuMimi C Yu
Jun 28, 2012·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Barbara J FuhrmanGretchen L Gierach
Jan 1, 2010·Nutrients·Gertraud MaskarinecJeffrey A Tice
Apr 10, 2009·The American Journal of Clinical Nutrition·Johanna W Lampe
May 28, 2010·The Journal of Nutrition·Johanna W Lampe
Feb 28, 2013·Public Health Nutrition·Taisha DooGertraud Maskarinec
May 31, 2011·Reproductive Toxicology·Nadine M BrownKenneth D R Setchell
Nov 11, 2008·Toxicology and Applied Pharmacology·Rohit SinghalMartin J Ronis
Mar 29, 2011·Critical Reviews in Toxicology·Susanne AndresAlfonso Lampen
Feb 19, 2015·Journal of Women's Health·Wulf H UtianKenneth D R Setchell
Apr 12, 2014·International Journal of Food Sciences and Nutrition·Xin RuiMingsheng Dong
Sep 11, 2013·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Marilyn TsengCarolyn Y Fang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.